Law360, New York ( November 4, 2015, 12:55 PM EST) -- In recent years, a small crop of complaints have alleged that brand pharmaceutical companies take advantage of distribution restrictions in U.S. Food and Drug Administration-imposed "risk evaluation and mitigation strategy" — or REMS — programs to delay or block generic competition.[1] Recently, district courts issued motion to dismiss decisions in two such cases: Natco Pharma Ltd. v. Gilead Sciences Inc. and Express Scripts Holding Co.[2] and In re Thalomid and Revlimid Antitrust Litigation.[3]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.